These results suggest that Shp2 contributes to the EGFR mutant-induced lung tumorigenesis and that inhibiting the PTP activity of Shp2 can suppress EGFR mutant-induced lung adenocarcinomas. The gene discussed is PTPN11; the disease is lung adenocarcinoma.